within Pharmacolibrary.Drugs.C_CardiovascularSystem.C10B_LipidModifyingAgentsCombinations.C10BA07_RosuvastatinAndOmega3FattyAcids;
model RosuvastatinAndOmega3FattyAcids 
   extends Pharmacolibrary.Drugs.ATC.C.C10BA07;

  annotation(Documentation(
    info ="<html><body><p>Rosuvastatin and omega-3 fatty acids is a fixed-dose combination used for the treatment of dyslipidemia, particularly in patients who require lowering of LDL cholesterol and triglycerides simultaneously. Rosuvastatin is a statin that inhibits HMG-CoA reductase, effectively reducing cholesterol biosynthesis, while omega-3 fatty acids (EPA/DHA) reduce triglyceride levels. The combination may enhance lipid profile improvements compared to monotherapy. The drug is approved and used in several countries for the management of mixed dyslipidemia or hypertriglyceridemia.</p><h4>Pharmacokinetics</h4><p>There are no published population pharmacokinetic (PK) studies on the fixed combination of rosuvastatin and omega-3 fatty acids (C10BA07). Pharmacokinetic parameters are estimated based on published data for rosuvastatin 10 mg oral (single dose) and omega-3 acid ethyl esters (approx. 1000 mg EPA+DHA) in healthy adults. Parameters represent healthy adult population.</p><h4>References</h4><ol><li><p>Rehman, M, et al., &amp; Khalid, Q (2022). Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs. <i>Journal of visualized experiments : JoVE</i> None(185) â€“. DOI:<a href=&quot;https://doi.org/10.3791/63995&quot;>10.3791/63995</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35969097/&quot;>https://pubmed.ncbi.nlm.nih.gov/35969097</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end RosuvastatinAndOmega3FattyAcids;
